Neurim prevails against Mylan in suit over insomnia drug
Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.
Number of pay-for-delay deals remains low, says FTC
The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.
Illumina, Roche accused of infringing genetic testing patents
Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.
Abbott must face HIV testing patent suit, rules judge
Abbott Laboratories must face allegations brought by Grifols Diagnostic and a Novartis subsidiary that its HIV testing products infringe a patent covering a method to create HIV proteins using recombinant DNA.
Amgen, Teva to face Sensipar monopoly claims
Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.
Teva urges Fed Circuit to save skinny label law from ‘nullification’
Teva has urged the US Court of Appeals for the Federal Circuit to rehear its dispute with GlaxoSmithKline en banc, claiming that if the decision is upheld, “every skinny-labelled generic is at risk”.
Siemens drops heart catheter trade secret suit
A medical technology subsidiary of Siemens has settled a lawsuit against a former vice president, who it accused of stealing trade secrets related to heart catheter devices.
ICE targets COVID-19 vaccine fraud after seizing proceeds worth $26m
The US Immigration and Customs Enforcement has unveiled the next stage of its operation to combat a wave of fraudulent vaccines and treatments, after seizing more than $26 million in illicit proceeds from COVID-19 related products over the past six months.
CMA reveals antitrust investigation into Essential Pharma over bipolar drug
The UK Competition and Markets Authority is investigating Essential Pharma over suspicions that the pharmaceutical company contravened competition law by proposing to withdraw the supply of Priadel, a lithium-based medication for bipolar disease.
Wyeth secures Australian injunction against MSD vaccine
The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.
